SCHEMBL6986943

SCHEMBL6986943

COc1ccc2c(c1)NC=CO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.41
NOX1 Q9Y5S8 2/20 0.39
PSMB8 P28062 2/20 0.37
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
MAPT P10636 4/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 3/20 0.36
GFER P55789 2/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GAA P10253 2/20 0.36
MAPK1 P28482 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA12 O43570 3/20 0.35
CA9 Q16790 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8751791 0.86 SNCA (0.41) SNCANOX1MEN1KMT2AMAPT
SCHEMBL8470299 0.69 SNCA (0.42) SNCANOX1MEN1KMT2AMAPT
SCHEMBL7107394 0.68 POLB (0.36) NOX1MEN1KMT2AMAPTALDH1A1
SCHEMBL5515460 0.68 ALDH1A1 (0.42) ALDH1A1KDM4ETSHRHSD17B10TDP1
SCHEMBL224635 0.66 ALOX5 (0.41) GAALMNAHTTSMN1; SMN2
SCHEMBL1443332 0.66 CA2 (0.46) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL1247719 0.64 GAA (0.43) SNCANOX1MEN1KMT2AMAPT
SCHEMBL4695235 0.64 CA12 (0.49) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL293466 0.64 PARP1 (0.57) MEN1KMT2AALDH1A1HSD17B10GAA
SCHEMBL29242101 0.63 SNCA (0.63) SNCANOX1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6620809-B2 Useful in treating or in preventing melatoninergic disorders LES LABORATOIRES SERVIER (FR) 2003-09-16 US disclosed
EP-1106608-B1 Substituted (dihydro)benzoxazine and (dihydro)benzothiazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-03-05 EP disclosed
US-20010003747-A1 New substituted (dihydro)benzoxazine and (dihydro)benzothiazine compounds LES LABORATOIRES SERVIER (FR) 2001-06-14 US disclosed
EP-1106608-A1 Substituted (dihydro)benzoxazine and (dihydro)benzothiazine derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003747-A1 New substituted (dihydro)benzoxazine and (dihydro)benzothiazine compounds MTNR1A, MTNR1B, SQOR SNCA 1146/4885NOX1 267/4885PSMB8 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.